Table 4 The effect of subsequent radiotherapy and/or chemotherapy on the risk of developing thyroid disorders in head and neck cancer patients
PTE + ND | PTE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Non-RT & Non-CT (N = 5319) | RT only (N = 597) | CT only (N = 251) | CCRT (N = 1133) | Sequential CT + RT (N = 160) | Non-RT, Non-CT (N = 3079) | RT only (N = 264) | CT only (N = 122) | CCRT (N = 239) | Sequential CT + RT (N = 26) | |
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Thyroid disorders | 71 (1.33) | 25 (4.19) | 2 (1.64) | 22 (1.94) | 2 (1.25) | 41 (1.33) | 5 (1.89) | 0 (0.00) | 4 (1.67) | 0 (0.00) |
Crude HR | 1 | 3.70 (2.34–5.83)* | 0.58 (0.14–2.35) | 1.75 (1.08–2.82)* | 1.10 (0.27–4.47) | 1 | 1.47 (0.58–3.71) | – | 1.47 (0.53–4.12) | – |
Adjusted HR | 1 | 3.64 (2.28–5.81)* | 0.58 (0.14–2.36) | 1.70 (1.05–2.77)* | 1.01 (0.25–4.14) | 1 | 1.41 (0.56–3.58) | – | 1.51 (0.54–4.23) | – |
CRR | 1 | 3.00 (1.89–4.77)* | 0.49 (0.12–2.02) | 1.19 (0.74–1.93) | 0.73 (0.18–2.98) | 1 | 1.21 (0.48–3.05) | – | 1.09 (0.38–3.11) | – |